














Randomized trial of minocycline in the
treatment of HIV-associated cognitive
impairment
ABSTRACT
Objective: To evaluate the efficacy and safety of minocycline in themanagement of HIV-associated
cognitive impairment.
Methods: We enrolled HIV-positive participants with a CD4 count of 250 to 500 cells/mL in a
randomized, double-blind, placebo-controlled study. They received 100 mg of minocycline or
matching placebo orally every 12 hours for 24 weeks. Cognitive function was measured using
the Uganda Neuropsychological Test Battery Summary Measure (U NP Sum) and the Memorial
Sloan-Kettering (MSK) scale. The primary efficacy measure was the 24-week change in an aver-
age of 9 standardized U NP Sum z scores.
Results: Seventy-three participants were enrolled. Of these, 90% were female, 49% were
between the ages 30 and 39 years, and 74% had 6 or more years of education. One partici-
pant had MSK score of stage 1 (i.e., mild HIV dementia), and 72 participants had MSK stage
0.5 (i.e., equivocal or subclinical dementia) at the baseline evaluation. The minocycline effect
on the 24-week change of the U NP Sum compared with placebo was 0.03 (95% confidence
interval 20.51, 0.46; p 5 0.37).
Conclusion: Minocycline was safe and well tolerated in HIV-positive individuals. However, it did
not improve HIV-associated cognitive impairment.
Classification of evidence: This study provides Class II evidence that 100 mg of minocycline given
orally every 12 hours for 24 weeks had no significant effect compared with placebo in the
improvement of cognitive function in antiretroviral therapy–naive, HIV-positive patients.
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GLOSSARY
cART 5 combination antiretroviral therapy; CI 5 confidence interval; DSMB 5 Data Safety and Monitoring Board; IADL 5
Instrumental Activities of Daily Living; RCI 5 reliable change index; U NP Sum 5 Uganda Neuropsychological Test Battery
Summary Measure; WHO-UCLA 5 World Health Organization–University of California at Los Angeles.
Although combination antiretroviral therapy (cART) improves cognitive impairment,1 the treat-
ment response may be unsatisfactory or short-lived, or the agents may be poorly tolerated in
doses adequate for CNS penetration.2–4 In Uganda as well as some other African countries,
almost 50% of cART-eligible patients, even those with HIV cognitive impairment, remain
untreated.5–8
Sequestration of the HIV virus in brain tissue may require an adjunct potent drug that can cross
the blood-brain barrier with the ability to interfere with the inflammatory events of HIV infection
and improve the management of HIV cognitive impairment. Minocycline would offer a unique
therapeutic strategy for HIV-associated neurocognitive disorders because of its antiinflammatory
and neuroprotective effects as has been noted in in vivo studies.9–14 To validate these findings,
we hypothesized that minocycline treatment for 24 weeks would improve HIV-associated cogni-
tive impairment and would be safe and well tolerated in individuals with HIV.
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We thus conducted a phase I/II, randomized,
double-blind, placebo-controlled study to assess
the efficacy, tolerability, and safety of minocy-
cline for the treatment of HIV-associated cogni-
tive impairment in Uganda. In contrast to a
prior study15 in the United States in which all
HIV-positive individuals were receiving cART,
this study was conducted in HIV-positive indi-
viduals who were not eligible for ART in
the Uganda setting. Thus, the direct effect
of minocycline and placebo in the absence of
ART was examined in this study.
METHODS Recruitment/enrollment. During the screen-
ing process from April 2008 to September 2009, we selected
every fifth patient out of a list of ART-naive, HIV-positive
patients with a CD4 count in the range of 250 to 500 cells/mL
who presented on each clinic day at the Infectious Diseases
Clinic, Kampala, Uganda. This specialized outpatient HIV health
unit offers free care and serves as a national referral center, pro-
viding specialist consultations for infected patients including
those who are not responding to treatment from other health
facilities. More than 9,000 HIV/AIDS clients have been regis-
tered since its establishment in 2004.
The screening included a measure for cognitive impairment
using the 0- to 12-point International HIV Dementia Scale.16
Any person scoring #10 points was suspected of having HIV
dementia as previously determined during the validation of the
instrument. Two research assistants administered a detailed neu-
ropsychological test battery that included the Timed Gait,
Grooved Pegboard Dominant Hand, Grooved Pegboard Non-
dominant Hand, Color Trails 1, Color Trails 2, Symbol Digit,
World Health Organization–University of California at Los An-
geles (WHO-UCLA) Verbal Learning Test trial 5, WHO-UCLA
Verbal Learning Test delayed recall, and Digit Span forward and
Digit Span backward.
The selection criteria for the study participants are shown in
table 1. The study had 2 steps: step 1 was the double-blind phase
in which individuals received minocycline or placebo for 24
weeks; step 2, an optional open phase, was available for those
who completed step 1 and every participant who agreed to enroll
received minocycline for 24 additional weeks.
Standard protocol approvals, registrations, and patient
consents. The study clinical trial identifier number in Clin-
icalTrials.gov was NCT00855062.
The Makerere University School of Medicine Research and
Ethics Committee as well as the Uganda National Council for
Science and Technology approved the use of human subjects.
All participants gave informed consent before enrollment into
the study.
Intervention. In this double-blind, placebo-controlled study,
we randomized 73 participants to receive either 100 mg
of minocycline orally every 12 hours or matching placebo orally
every 12 hours daily for 24 weeks. We performed a neurologic
examination and safety laboratory tests including serum chemis-
try profiles (electrolytes, liver function tests), hematology, and
CD4 lymphocyte counts at screening and weeks 4, 12, and 24.
A neuropsychological test battery was performed at screening,
entry, 12 weeks, and 24 weeks. The presence of depression symp-
tomatology was assessed with the Center for Epidemiologic
Studies Depression Scale.17 We measured the participants’ func-
tional performance with the Karnofsky scale and Instrumental
Activities of Daily Living (IADL). Individuals who had higher
scores on the Karnofsky scale at subsequent visits compared with
the baseline score were considered to be “better” in their func-
tional performance. The level of cognitive function was scored
using the Memorial Sloan-Kettering scale.
The participants were randomly assigned to a treatment
group based on a preassigned randomization list. The list was kept
by the study pharmacist who had no access to the patients’ clinical
evaluations both at baseline and through follow-up. Once a
patient had been screened and found fit for the study, the research
assistant would notify the pharmacist of the participant. The
pharmacist would then assign a number in the randomization list
as appropriate.
Outcome measures. The primary objective of the study was
the change in neurocognitive performance from baseline to 24
weeks as measured by the Uganda Neuropsychological Test Bat-
tery Summary Measure (U NP Sum). Each test score was stan-
dardized to normal, 1, or 2 SDs from the mean in comparison
to normative values of an age-, sex-, and education-matched gen-
eral non-HIV population.18 The U NP Sum was defined as the
mean of the z scores of the following tests: Grooved Pegboard
Dominant Hand, Grooved Pegboard Nondominant Hand, Color
Trails 1, Color Trails 2, Symbol Digit, WHO-UCLA Verbal
Learning Test trial 5 total, WHO-UCLA Verbal Learning Test
delayed recall, Digit Span forward, and Digit Span backward. The
secondary objective of the study was the measure of safety includ-
ing the frequency of adverse events and abnormal results on lab-
oratory tests, and changes over time in vital signs and symptoms.
Statistical methods. The primary analysis followed the intention-
to-treat principle, and all 73 randomized participants were included.
Table 1 Eligibility criteria
Inclusion criteria
Naive to antiretroviral therapy with CD4 count 250–350
AIDS Dementia Scale stage 0.5 or 1
International HIV Dementia Scale score #10
Ability to sit or stand and swallow intact capsules with an
8-oz. glass of water
Resident within a 20-km radius of Kampala city
HIV-1 infection before study entry
Female subjects of reproductive potential with a negative
serum or urine pregnancy test within 48 h before study
entry
Exclusion criteria
,18 or .65 years of age
Karnofsky scale functional performance score ,50
Pregnant or breast-feeding
Unwilling to use effective barrier birth control methods
Active symptomatic AIDS defining opportunistic infection
Current neoplasm
Severe premorbid psychiatric illness
Confounding neurologic disorder, CNS infection, active
drug or alcohol use or dependence, serious illness requiring
systemic treatment that would interfere with the study
requirements, a history of an allergy or sensitivity
to minocycline or another tetracycline
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The number needed to treat was 25. Because the primary end point
was a continuous variable, a new dichotomous variable (05 did not
reach a clinically meaningful cutoff of 0.5; 1 5 reached the cutoff)
was created and the proportions of participants who reached the
clinically meaningful cutoff from the minocycline and control groups
were used to calculate the number needed to treat.
The study sample size was arrived at by assuming that both
arms (minocycline and placebo) would have an SD of 0.7 in
the 24-week change in U NP Sum, a 17% loss-to-follow-up rate,
10% noncompliance, and Pitman efficiency of 0.864. To be able
to detect a difference of 0.5 (a minimum clinically relevant differ-
ence) in the 24-week U NP Sum changes with 85% power and a
type I error rate of 0.05 required 100 subjects (50 per group).
Because 19% of participants had missing 24-week U NP Sum
for various dropout reasons, the missing values were imputed by a
multiple regression imputation method. Once all values were
imputed, a regression model was fit to estimate the efficacy
of minocycline on the 24-week change of U NP Sum, adjusting
for the baseline U NP Sum. Two different sensitivity analyses
were also conducted: 1) a linear regression model based on
observed outcomes, and 2) a mixed model with all observed
and repeatedly measured outcomes. All secondary analyses were
based on observed data. For continuous outcomes, linear regres-
sion models adjusting for a baseline score were used, and for cat-
egorical outcomes, logistic regression models were used. For both
primary and secondary analyses, the Bonferroni correction was
applied on type I error to adjust for multiplicity.
We also examined the primary objective using the reliable
change index (RCI). The RCIs between the minocycline and pla-
cebo groups were compared using a z test to determine the effect
on the 24-week change of U NP Sum.
Classification of evidence. The primary research question for
this study was: Does minocycline improve cognitive function
among HIV-positive individuals? This intervention study pro-
vides Class II evidence that minocycline treatment of 100 mg
given orally every 12 hours for 24 weeks does not improve
HIV-associated cognitive impairment among HIV-positive indi-
viduals with a CD4 count of 250 to 500 cells/mL (minocycline
effect on the 24-week change of cognitive function compared
with placebo was 20.03, 95% confidence interval [CI] 20.51
to 0.46; p 5 0.37).
RESULTS The study was initially planned to enroll
100 participants. After half the participants com-
pleted the double-blind phase, an interim analysis
of primary and secondary outcome measures was per-
formed and reviewed by the Neurological AIDS
Research Consortium Data Safety and Monitoring
Board (DSMB). The DSMB recommended early ter-
mination of the study because of outcome futility,
and participants were informed and discharged after
completing the final study visits. The overall accrual
and study step discontinuation in each study arm are
summarized in the figure. Of 73 randomized partici-
pants, 52 (71%) completed the 24-week protocol, and
28 (38%) completed the 48-week protocol. As shown
in table 2, 90% of the participants were women. The
modal age group was 30 to 39 years (49%) and most
(53%) had received 6 to 10 years of education. The
treatment arms were similar in baseline characteristics.
Only 1 participant in the minocycline arm had stage-
1 dementia (i.e., mild HIV dementia), and the remain-
der of the 72 participants had stage 0.5 (i.e., equivocal
or subclinical dementia). The minocycline effect on the
24-week change of the U NP Sum compared with pla-
cebo was 20.03 (95% CI 20.51, 0.46; p 5 0.37)
(table 3). The upper CI did not reach the prespecified
clinically meaningful cutoff point of 0.5, and this result
rules out a significant minocycline effect compared with
placebo. The effect of minocycline on the 24-week
change in the CD4 cell count after adjusting for the
baseline CD4 count was 8.11 (95%CI227.23, 43.45;
p value 5 0.65). The mean CD4 count decreased by
25 cells/mL in the minocycline arm and by 28 cells/mL
in the placebo arm; however, this was not significantly
different. Two participants (6%) in the placebo arm
and 1 participant (3%) in the minocycline arm had
improved score on the Karnofsky functional perfor-
mance scale at week 24 compared with baseline (95%
CI 0.04, 0.06; p 5 0.61). Four participants (14%) in
the minocycline arm and 3 participants (12%) in the
placebo arm had an improved IADL score at week 24
compared with their baseline. The treatment effect on
the IADL (estimated by odds ratio) was 1.28 (95% CI
0.26, 6.34; p 5 0.76). The 95% CI of being “better"
for the minocycline arm was 0.05, 0.37 and 0.03, 0.34
for the placebo arm.
None of the secondary cognitive outcome meas-
ures showed a difference between the 2 treatment
arms with one exception. The 24-week change of
the delayed verbal memory recall in a general linear
model adjusting for baseline neuropsychological test
score showed a benefit for the placebo arm of
20.718 (95% CI 21.35, 20.08; p value 5 0.03).
The mean (SD) RCI for the minocycline and pla-
cebo groups was 0.84 (1.43) and 0.95 (1.28), respec-
tively. The minocycline effect on the 24-week change
of U NP Sum compared with the placebo effect was
not statistically significant ( p5 0.76). There were no
significant differences between the minocycline and
placebo arms on the subjective and performance-
based functional measures, measures of mood, or viral
load assessments.
Safety. Of note were 7 cases (19.4%) of grade-2
hyperpigmentation that occurred among patients
taking minocycline. This usually happened by week
12; however, the condition would resolve by the sub-
sequent clinic visits. Two patients experienced a
grade-4 rash related to the study drug. The probabil-
ity of not experiencing any signs and symptoms by
week 24 was higher for the minocycline group but
was not significantly different from the placebo arm
using the log-rank test (p 5 0.58).
There was 1 death that was unrelated to study
drug. This patient had only 11% adherence to study
drug at the end of the fourth week after
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randomization. In the sixth week, the study drug was
withdrawn after continuing adherence problems. She
was later diagnosed to be coinfected with pulmonary
tuberculosis, to which she later succumbed.
DISCUSSION In this randomized, double-blind,
placebo-controlled study, 100 mg of minocycline given
orally every 12 hours had no significant effect over pla-
cebo in the improvement of cognitive function in ART-
naive, HIV-positive patients. The drug, however, was
safe and well tolerated. Apart from the delayed verbal
recall test, there were no differences detected among
the 2 arms in the change scores for the secondary out-
come measures of neuropsychological test performance.
The level of functional improvement between the 2
study arms was similar. These results are consistent with
a second trial of minocycline for the treatment of HIV-
associated cognitive impairment recently performed in
HIV-positive individuals with neurocognitive impair-
ment on cART.15
Cognitive impairment as seen in the study popu-
lation continues to be an important manifestation
of HIV infection, affecting 40% to 60% of HIV sero-
positive individuals even after the initiation of highly
active antiretroviral therapy.19 The cognitive impair-
ment observed in this particular study group could
also have been due to non-HIV comorbid infections
or conditions. Hepatitis C infection is one such
condition but it is rare among HIV-positive individ-
uals in Uganda, with a prevalence of 3%,20,21 and thus
an unlikely cause for the observations made. Tuber-
culosis with CNS involvement can affect the level of
consciousness and consequently the level of cognitive
function.22 However, the screening criteria for this
particular study excluded all subjects who had evi-
dence of an active tuberculous infection. Nutritional
deficiencies including micronutrients can be a pri-
mary causative factor in HIV disease progression,
thereby contributing to cognitive dysfunction.23
The population in this study, however, was mostly
observed to be adequately nourished.
There are usually differences in response to phar-
macologic agents among males and females. Our
study population was mostly female and thus the
low number of males may have obscured sex effects
of performance on tests as well as the effects of the
investigational drug.
Other factors such as depression or side effects from
medications have also been associated with cognitive
impairment.24 We screened for depression with the
Center for Epidemiologic Studies Depression Scale,
and the study sample had equal distribution of indi-
viduals with the same range of symptoms within the
placebo and minocycline arms. All study participants
were prescribed trimethoprim-sulfamethoxazole for
Figure Participant flow chart
ART 5 antiretroviral therapy.
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prophylaxis in compliance with Uganda treatment
guidelines. This drug has no known effects on cogni-
tive function.
The early penetration of the HIV virus into brain tis-
sue leads to sequestration of the virus,25 and therefore
the minocycline dose of 200 mg/d used in the study
may have been inadequate to change inflammatory
events or provide neuroprotective properties within
the CNS even though minocycline has relatively good
brain penetration.26,27 In addition, neuronal injury or
dysfunction occurs early in HIV infection, and may
be unresponsive to potential antiinflammatory or neuro-
protective effects of minocycline started during late-stage
HIV infection. Surrogate markers such as neuroimaging
or CSF biomarkers may be needed to evaluate early
evidence of neuroprotection within the CNS rather than
the clinical neuropsychological tests and functional out-
comes used in this evaluation. The duration of observa-
tion for cognitive change was relatively short; evaluations
conducted for a longer period of time could possibly
yield different results. The neurocognitive testing was
conducted 3 times in the 24 weeks, and this may have
resulted in practice effects that may have contributed to
the improvement in both groups and thus may have
obscured differences between the minocycline and
placebo groups. Unfortunately, this kind of evaluation
was not designed for this study. Interestingly, the prob-
ability of individuals not experiencing signs and symp-
toms of “any cause” was higher in the minocycline arm
compared with placebo by week 24. The signs and
symptoms included any clinical event such as cough,
fever, and nausea, among others, and the patients seemed
to fare better on the treatment. This may be secondary to
the antiinflammatory properties offered by the drug.28
Minocycline has been shown to have a neuropro-
tective effect in animal models for a variety of neuro-
logic conditions.13,29 In humans, the drug has been
shown to have therapeutic benefit in clinical trials of
multiple sclerosis and stroke.10,30 However, in a study
of 412 individuals with amyotrophic lateral sclerosis,









Total (N 5 73),
mean (SD)
Minocycline
effecta 95% CI p Value
WHO-UCLA VLT trials total 0.64 (1.06) 1.20 (1.26) 0.91 (1.18) 20.50 21.04, 0.05 0.08
WHO-UCLA VLT delayed 0.46 (1.17) 1.18 (1.53) 0.81 (1.39) 20.72 21.35, 20.08 0.03
Color Trails 1 20.51 (2.25) 20.37 (2.38) 20.44 (2.30) 0.24 20.70, 1.18 0.61
Color Trails 2 20.80 (2.35) 20.85 (1.75) 20.83 (2.05) 0.27 20.57, 1.12 0.52
Digit Span forward 0.20 (0.89) 0.06 (0.79) 0.13 (0.84) 20.01 20.42, 0.40 0.96
Digit Span backward 20.03 (0.93) 20.03 (1.07) 20.03 (0.99) 0.07 20.38, 0.51 0.76
Grooved Pegboard Dominant 20.53 (1.51) 20.04 (1.37) 20.29 (1.46) 20.31 20.89, 0.28 0.30
Grooved Pegboard Nondominant 20.67 (1.55) 20.53 (1.31) 20.61 (1.43) 0.05 20.49, 0.58 0.86
Symbol Digit 0.23 (0.72) 0.23 (0.57) 0.23 (0.65) 0.04 20.29, 0.36 0.83
U NP Sum 0.44 (0.74) 0.49 (0.67) 0.46 (0.70) 20.03 20.51, 0.46 0.37
Abbreviations: CI 5 confidence interval; U NP Sum 5 Uganda Neuropsychological Test Battery Summary Measure; WHO-
UCLA VLT 5 World Health Organization–University of California at Los Angeles Verbal Learning Test.
a The minocycline effect was estimated by a linear regression, adjusted for the baseline score.








Male 2 (6) 5 (14) 7 (10)
Female 34 (94) 32 (86) 66 (90)
Age, y, n (%)
20–29 5 (14) 7 (19) 12 (16)
30–39 20 (56) 16 (43) 36 (49)
40–60 11 (31) 14 (38) 25 (34)
Years of education, n (%)
0–5 8 (23) 11 (30) 19 (26)
6–10 22 (61) 17 (46) 39 (53)
11–15 6 (17) 9 (24) 15 (21)
CD4 count, mean (SD) 324 (56) 316 (48) 320 (52)
Log10 (RNA viral load), mean (SD) 4.41 (0.74) 4.59 (0.72) 4.50 (0.73)
MSK score, n (%)
Equivocal 35 (97) 37 (100) 72 (99)
Mild 1 (3) 0 (0) 1 (1)
Karnofsky score, n (%)
80 1 (3) 2 (5) 3(4)
90–100 35 (97) 35 (95) 70 (96)
Abbreviation: MSK 5 Memorial Sloan-Kettering.
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participants taking minocycline deteriorated more
quickly as measured by the amyotrophic lateral scle-
rosis functional rating scale of gross and fine motor
tasks, bulbar function, and respiratory function com-
pared with those receiving placebo.31
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Editor’s Note to Authors and Readers: Levels of Evidence in Neurology®
Effective January 15, 2009, authors submitting Articles or Clinical/Scientific Notes to Neurology® that report on clinical
therapeutic studies must state the study type, the primary research question(s), and the classification of level of evidence assigned
to each question based on the classification scheme requirements shown below (left). While the authors will initially assign a
level of evidence, the final level will be adjudicated by an independent team prior to publication. Ultimately, these levels can be
translated into classes of recommendations for clinical care, as shown below (right). For more information, please access the
articles and the editorial on the use of classification of levels of evidence published in Neurology.1-3
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